A multi-center, placebo-controlled, randomized Phase 2 study of Triplex for control of CMV in patients undergoing liver transplantation

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Mar 2025 According to a Fortress Biotech media release, the first patient was been dosed in May 2024.
31 Mar 2025 Status changed from planning to recruiting, according to a Fortress Biotech media release
15 Jun 2023 According to a Helocyte media release, the company announced that the National Cancer Institute has awarded a 3.22 million dollars grant to City of Hope for clinical studies of Triplex, a cytomegalovirus vaccine being developed by Helocyte and City of Hope.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com